{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:27:16Z","timestamp":1772105236838,"version":"3.50.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000085","name":"Ontario HIV Treatment Network","doi-asserted-by":"publisher","award":["EFP-1096-Junior Inv"],"award-info":[{"award-number":["EFP-1096-Junior Inv"]}],"id":[{"id":"10.13039\/501100000085","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Research Institute of St. Joe\u2019s Hamilton","award":["Constantine Douketis New Researcher Award"],"award-info":[{"award-number":["Constantine Douketis New Researcher Award"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Knowledge of HIV drug resistance informs the choice of regimens and ensures that the most efficacious options are selected. In January 2014, a policy change to routine resistance testing was implemented in Ontario, Canada. The objective of this study was to investigate the policy change impact of routine resistance testing in people with HIV in Ontario, Canada since January 2014.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We used data on people with HIV living in Ontario from administrative databases of the Institute for Clinical Evaluative Sciences (ICES) and Public Health Ontario (PHO), and ran ordinary least squares (OLS) models of interrupted time series to measure the levels and trends of 2-year mortality, 2-year hospitalizations and 2-year emergency department visits before (2005\u20132013) and after the policy change (2014\u20132017). Outcomes were collected in biannual periods, generating 18 periods before the intervention and 8 periods after. We included a control series of people who did not receive a resistance test within 3 months of HIV diagnosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Data included 12,996 people with HIV, of which 8881 (68.3%) were diagnosed between 2005 and 2013, and 4115 (31.7%) were diagnosed between 2014 and 2017. Policy change to routine resistance testing within 3 months of HIV diagnosis led to a decreasing trend in 2-year mortality of 0.8% every six months compared to the control group. No significant differences in hospitalizations or emergency department visits were noted.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Interpretation<\/jats:title>\n<jats:p>The policy of routine resistance testing within three months of diagnosis is beneficial at the population level.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0246766","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T17:22:38Z","timestamp":1617384158000},"page":"e0246766","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of routine HIV drug resistance testing in Ontario: A controlled interrupted time series study"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5855-5461","authenticated-orcid":true,"given":"Lawrence","family":"Mbuagbaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen H.","family":"Logie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Smaill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Smieja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann N.","family":"Burchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Rachlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Eric","family":"Tarride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Kroch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Mazzulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daeria O.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-1714","authenticated-orcid":true,"given":"Hsien","family":"Seow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"pone.0246766.ref001","unstructured":"UNAIDS. Global HIV & AIDS statistics\u20142018 fact sheet 2019 [cited 2020 20 January]. Available from: http:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"pone.0246766.ref002","unstructured":"WHO. HIV\/AIDS: Treatment and care 2019 [cited 2019 09 September]. Available from: https:\/\/www.who.int\/hiv\/topics\/treatment\/en\/."},{"key":"pone.0246766.ref003","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","author":"RK Gupta","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"9849","key":"pone.0246766.ref004","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"RK Gupta","year":"2012","journal-title":"Lancet"},{"issue":"Suppl 2","key":"pone.0246766.ref005","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/infdis\/jit111","article-title":"Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings","volume":"207","author":"V Cambiano","year":"2013","journal-title":"J Infect Dis"},{"issue":"17","key":"pone.0246766.ref006","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMp1710608","article-title":"HIV Drug Resistance\u2014An Emerging Threat to Epidemic Control","volume":"377","author":"C Beyrer","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"pone.0246766.ref007","unstructured":"WHO. Guidelines on the public health response to pretreatment HIV drug resistance 2017 [cited 2020 25 November]. Available from: https:\/\/bit.ly\/2C5GI7T."},{"key":"pone.0246766.ref008","unstructured":"WHO. HIV drug resistance report 2019 2019 [cited 2019 19 September]. Available from: https:\/\/www.who.int\/hiv\/pub\/drugresistance\/hivdr-report-2019\/en\/."},{"issue":"1","key":"pone.0246766.ref009","first-page":"17","article-title":"Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world","volume":"14","author":"D Frentz","year":"2012","journal-title":"AIDs Rev"},{"issue":"11","key":"pone.0246766.ref010","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/jac\/dks287","article-title":"Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002\u201309","volume":"67","author":"AN Burchell","year":"2012","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"9","key":"pone.0246766.ref011","doi-asserted-by":"crossref","first-page":"e0184848","DOI":"10.1371\/journal.pone.0184848","article-title":"Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada","volume":"12","author":"G Rocheleau","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"pone.0246766.ref012","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of hiv infection in adults: 2016 recommendations of the international antiviral society\u2013usa panel","volume":"316","author":"HF G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"pone.0246766.ref013","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-151-2-200907210-00003","article-title":"The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study","volume":"151","author":"FJ Palella","year":"2009","journal-title":"Ann Intern Med"},{"key":"pone.0246766.ref014","article-title":"Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States","author":"EP Hyle","year":"2019","journal-title":"Clinical Infectious Diseases"},{"key":"pone.0246766.ref015","unstructured":"CATIE. The epidemiology of HIV in Canada 2017 [cited 2020 17 August]. Available from: http:\/\/www.catie.ca\/en\/fact-sheets\/epidemiology\/epidemiology-hiv-canada."},{"key":"pone.0246766.ref016","unstructured":"CATIE. Progress on Ontario\u2019s HIV care cascade 2015 [cited 2020 25 November]. Available from: http:\/\/www.catie.ca\/en\/catienews\/2015-09-09\/progress-ontario-s-hiv-care-cascade."},{"issue":"12","key":"pone.0246766.ref017","doi-asserted-by":"crossref","first-page":"348","DOI":"10.14745\/ccdr.v44i12a03","article-title":"Adult immunization: HIV in Canada\u2014Surveillance Report, 2017","volume":"44","author":"N Haddad","year":"2018","journal-title":"Canada Communicable Disease Report"},{"key":"pone.0246766.ref018","unstructured":"PHO. HIV Genotyping, Resistance, Tropism and HLA-B*57:01 Abacavir Hypersensitivity Testing 2020 [cited 2020 27 August]. Available from: https:\/\/www.publichealthontario.ca\/en\/laboratory-services\/test-information-index\/hiv-drug-resistance-testing-genotyping."},{"issue":"6","key":"pone.0246766.ref019","doi-asserted-by":"crossref","first-page":"e21748","DOI":"10.1371\/journal.pone.0021748","article-title":"Validation of case-finding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection","volume":"6","author":"T Antoniou","year":"2011","journal-title":"PloS one"},{"issue":"1","key":"pone.0246766.ref020","doi-asserted-by":"crossref","first-page":"20634","DOI":"10.7448\/IAS.18.1.20634","article-title":"The HIV care cascade: a systematic review of data sources, methodology and comparability","volume":"18","author":"NA Medland","year":"2015","journal-title":"Journal of the International AIDS Society"},{"issue":"1","key":"pone.0246766.ref021","doi-asserted-by":"crossref","first-page":"e0210096","DOI":"10.1371\/journal.pone.0210096","article-title":"Trends in HIV care cascade engagement among diagnosed people living with HIV in Ontario, Canada: A retrospective, population-based cohort study.","volume":"14","author":"J Wilton","year":"2019","journal-title":"PLOS ONE"},{"issue":"10","key":"pone.0246766.ref022","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/09540121.2017.1338658","article-title":"Access and engagement in HIV care among a national cohort of women living with HIV in Canada","volume":"29","author":"N Kronfli","year":"2017","journal-title":"AIDS Care"},{"key":"pone.0246766.ref023","volume-title":"Ontario Marginalization Index user guide version 1.0","author":"F Matheson","year":"2012"},{"issue":"3","key":"pone.0246766.ref024","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1086\/644316","article-title":"Significance Testing with Population Data","volume":"59","author":"A Rubin","year":"1985","journal-title":"Social Service Review"},{"key":"pone.0246766.ref025","first-page":"h2750","volume":"350","author":"E Kontopantelis","year":"2015","journal-title":"Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis"},{"issue":"6","key":"pone.0246766.ref026","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/ije\/dyy135","article-title":"The use of controls in interrupted time series studies of public health interventions","volume":"47","author":"J Lopez Bernal","year":"2018","journal-title":"International journal of epidemiology"},{"issue":"11","key":"pone.0246766.ref027","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/jac\/dks287","article-title":"Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002\u201309","volume":"67","author":"AN Burchell","year":"2012","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"pone.0246766.ref028","first-page":"42","article-title":"Suboptimal use of HIV drug resistance testing in a universal health-care setting","volume":"23","author":"O Eyawo","year":"2011","journal-title":"AIDS Care\u2014Psychological and Socio-Medical Aspects of AIDS\/HIV"},{"issue":"1","key":"pone.0246766.ref029","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.9778\/cmajo.20180159","article-title":"Cause-specific mortality among HIV-infected people in Ontario, 1995\u20132014: a population-based retrospective cohort study","volume":"7","author":"AN Burchell","year":"2019","journal-title":"CMAJ open"},{"issue":"7624","key":"pone.0246766.ref030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Ev Elm","year":"2007","journal-title":"BMJ"},{"issue":"5","key":"pone.0246766.ref031","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/605292","article-title":"Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America","volume":"49","author":"JA Aberg","year":"2009","journal-title":"Clin Infect Dis"},{"key":"pone.0246766.ref032","unstructured":"EACS. European Guidelines for the treatment of people living with HIV (PLWH) in Europe 2019 [cited 2020 27 May]. Available from: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html."},{"issue":"3","key":"pone.0246766.ref033","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/QAI.0000000000002135","article-title":"Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals","volume":"82","author":"S Lodi","year":"2019","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"pone.0246766.ref034","article-title":"Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception","author":"R Zash","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"pone.0246766.ref035","doi-asserted-by":"crossref","first-page":"e1001124","DOI":"10.1371\/journal.pmed.1001124","article-title":"HIV, Gender, Race, Sexual Orientation, and Sex Work: A Qualitative Study of Intersectional Stigma Experienced by HIV-Positive Women in Ontario, Canada","volume":"8","author":"CH Logie","year":"2011","journal-title":"PLOS Medicine"},{"issue":"1","key":"pone.0246766.ref036","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12874-016-0247-7","article-title":"Why sex and gender matter in implementation research","volume":"16","author":"C Tannenbaum","year":"2016","journal-title":"BMC Medical Research Methodology"},{"key":"pone.0246766.ref037","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1742-4690-9-110","article-title":"Multiple choices for HIV therapy with integrase strand transfer inhibitors","volume":"9","author":"F Raffi","year":"2012","journal-title":"Retrovirology"},{"issue":"6","key":"pone.0246766.ref038","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-019-01108-x","article-title":"Drug Resistance During HIV Pre-Exposure Prophylaxis","volume":"79","author":"KM Gibas","year":"2019","journal-title":"Drugs"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T17:23:12Z","timestamp":1617384192000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246766"}},"subtitle":[],"editor":[{"given":"Yury E.","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0246766","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]}}}